Dual medications for depression increases costs, side effects with no benefit to patients

Taking two medications for depression does not hasten recovery from the condition that affects 19 million Americans each year, researchers at UT Southwestern Medical Center have found in a national study.

"Clinicians should not rush to prescribe combinations of antidepressant medications as first-line treatment for patients with ," said Dr. Madhukar H. Trivedi, professor of psychiatry and chief of the division of at UT Southwestern and principal investigator of the study, which is available online today and is scheduled for publication in an upcoming issue of the .

"The clinical implications are very clear – the extra cost and burden of two medications is not worthwhile as a first treatment step," he said.

In the Combining Medication to Enhance Depression Outcomes, or CO-MED, study, researchers at 15 sites across the country studied 665 patients ages 18 to 75 with major depressive disorder. Three treatment groups were formed and prescribed antidepressant medications already approved by the Food and Drug Administration. One group received escitalopram (a selective serotonin reuptake inhibitor, or SSRI) and a placebo; the second group received the same SSRI paired with bupropion (a non-tricyclic antidepressant); and a third group took different : venlafaxine (a tetracyclic antidepressant) and mirtazapine (a serotonin norepinephrine reuptake inhibitor). The study was conducted from March 2008 through February 2009.

After 12 weeks of treatment, remission and response rates were similar across the three groups: 39 percent, 39 percent and 38 percent, respectively, for remission, and about 52 percent in all three groups for response. After seven months of treatment, remission and response rates across the three groups remained similar, but side effects were more frequent in the third group.

Only about 33 percent of depressed patients go into remission in the first 12 weeks of treatment with antidepressant medication, as Dr. Trivedi and colleagues previously reported from the Sequenced Treatment Alternatives to Relieve Depression, or STAR*D, study. STAR*D was the largest study ever undertaken on the treatment of major depressive disorder and is considered a benchmark in the field of depression research. That six-year, $33 million study initially included more than 4,000 patients from sites across the country. Dr. Trivedi was a co-principal investigator of STAR*D.

The next step, Dr. Trivedi said, is to study biological markers of depression to see if researchers can predict response to antidepressant medication and, thus, improve overall outcomes.

Related Stories

Treating SSRI-resistant depression

Mar 25, 2008

When your antidepressant medication does not work, should you switch to a different medication from the same class or should you try an antidepressant medication that has a different mechanism of action" This is the question ...

Recommended for you

Study links suicide risk with insomnia, alcohol use

1 hour ago

A new study is the first to show that insomnia symptoms mediate the relationship between alcohol use and suicide risk, and that this mediation is moderated by gender. The study suggests that the targeted ...

Echolocation acts as substitute sense for blind people

7 hours ago

Recent research carried out by scientists at Heriot-Watt University has demonstrated that human echolocation operates as a viable 'sense', working in tandem with other senses to deliver information to people with visual impairment.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.